|
Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC). |
|
|
Stock and Other Ownership Interests - MolecularMatch; Navire |
Consulting or Advisory Role - Amal Therapeutics; Biocartis; EMD Serono; Genentech; Holy Stone Healthcare; Holy Stone Healthcare; Karyopharm Therapeutics; Merck; Navire; Roche; Symphogen |
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst) |
|
|
Consulting or Advisory Role - Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst) |
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Amgen; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; Merck Sharp & Dohme |
|
|
Research Funding - Array BioPharma; GlaxoSmithKline; Novartis |
Travel, Accommodations, Expenses - Array BioPharma |
|
|
Consulting or Advisory Role - Amgen; Lilly; Novartis; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Employment - Modra Pharmaceuticals |
Stock and Other Ownership Interests - Modra Pharmaceuticals |
Research Funding - Dutch Cancer Society (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Sirtex Medical |
Consulting or Advisory Role - Amgen; Array BioPharma; Genentech/Roche |
Speakers' Bureau - Amgen; Taiho Pharmaceutical |
Research Funding - Merck (Inst); Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Merck Serono |
|
|
Consulting or Advisory Role - Amgen; BeiGene; Bionomics; Eisai; Lilly; Novartis |
Research Funding - Bionomics (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche (Inst) |
|
|
Research Funding - Chugai Pharma (Inst); GlaxoSmithKline (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst) |
|
|
Consulting or Advisory Role - Amgen; Bayer; Merck; Roche; SERVIER |
Research Funding - Amgen; Bayer; Ipsen; Merck; Roche; SERVIER |
|
|
Honoraria - Array BioPharma; Celgene; Lilly; Merck KGaA; Servier; Sirtex Medical |
Speakers' Bureau - Celgene; Merck KGaA; Sirtex Medical |
Research Funding - Merck KGaA (Inst); Pfizer (Inst); Sirtex Medical (Inst) |
|
|
Employment - Array BioPharma |
Stock and Other Ownership Interests - Array BioPharma |
Travel, Accommodations, Expenses - Array BioPharma |
|
|
Employment - Array BioPharma |
Stock and Other Ownership Interests - Array BioPharma; Gilead Sciences |
|
|
Employment - Alnylam (I); Array BioPharma |
Stock and Other Ownership Interests - Alnylam (I); Array BioPharma |
Patents, Royalties, Other Intellectual Property - Receives royalties from Yale University on an antibody used in nephrology basic research. (I) |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER |
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst) |
|
|
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Genentech/Roche; Lilly; Merck Serono; MSD; Novartis; Roche; Sanofi; Symphogen; Taiho Pharmaceutical |